Tonix Pharmaceuticals Holding (TNXP) Research & Development: 2023-2025
Historic Research & Development for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to $9.3 million.
- Tonix Pharmaceuticals Holding's Research & Development rose 1.92% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year decrease of 26.55%. This contributed to the annual value of $40.0 million for FY2024, which is 53.87% down from last year.
- Latest data reveals that Tonix Pharmaceuticals Holding reported Research & Development of $9.3 million as of Q3 2025, which was down 14.15% from $10.8 million recorded in Q2 2025.
- Tonix Pharmaceuticals Holding's 5-year Research & Development high stood at $21.1 million for Q3 2023, and its period low was $7.4 million during Q1 2025.
- Moreover, its 3-year median value for Research & Development was $9.7 million (2024), whereas its average is $11.7 million.
- As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Research & Development plummeted by 56.70% in 2024, and later grew by 11.57% in 2025.
- Over the past 3 years, Tonix Pharmaceuticals Holding's Research & Development (Quarterly) stood at $17.1 million in 2023, then plummeted by 51.54% to $8.3 million in 2024, then climbed by 1.92% to $9.3 million in 2025.
- Its last three reported values are $9.3 million in Q3 2025, $10.8 million for Q2 2025, and $7.4 million during Q1 2025.